General presentation of Eli Lilly :
Let us now set off together to discover Eli Lilly and its various activities. This will allow you to understand how this value may behave in the coming months and years depending on the company's sources of revenue.
The Eli Lilly Group is an American company specialising in the pharmaceutical sector and is also one of the world leaders in this sector. In order to better understand the activities of this group, it is possible to divide them into different divisions according to the share of turnover they generate and in this way :
- Endocrinology generates 47.6% of the group's turnover with products to treat osteoporosis, diabetes and growth problems.
- Oncology generates 17.4% of turnover.
- Veterinary medicine generates 12.8% of the group's turnover.
- Cardiovascular diseases represent 9.2% of turnover.
- Neurology generates 7.4% of sales with drugs to treat depression and schizophrenia.
- Immune diseases account for 4.6% of turnover.
- Finally, the remaining 1% of turnover comes from other products.
It is also interesting to know the geographical distribution of Eli Lilly's revenues. The group generates 56.5% of its turnover in the United States, 17.2% in Europe, 10.2% in Japan and 16.1% in the rest of the world.
Know the competition of the Eli Lilly share :
Let's now discover the other major global players in this sector and thus Eli Lilly's direct competitors.
- Pfizer: This pharmaceutical company was founded in 1849 and operates in more than 150 countries. It is the world leader in its sector with a very large market capitalisation and turnover. Pfizer employs nearly 81,800 people worldwide.
- Sanofi: This French pharmaceutical group is active in several businesses including pharmaceuticals with products in the treatment of diabetes, rare diseases, multiple sclerosis, oncology, consumer and generic health products and vaccines.
- Astrazeneca : The Astrazeneca group is also one of the leaders in this pharmaceutical sector in the world. It was created in 1999 following the merger of the Swedish company Astra and the British company Zeneca.
- GlaxosmithKline or GSK: This British multinational is also one of the giants of the pharmaceutical industry in the world. It was created from the merger of Glaxo Wellcome and SmithKline Beecham in 2000.
- Bristol-Myers Squibb: This US pharmaceutical company has been in existence since 1989 and is the result of the merger of Bristol Myers Company and Squibb Corporation. Today and thanks to this merger, the group has become one of the largest in this sector.
- Merck: The Merck Group is a German company specialising in pharmaceuticals through Merck Serono, but also in chemicals.
- Roche Holding: This company is a Swiss pharmaceutical company and also one of the world's leading companies in this sector. It has been active since 2004 in two distinct sectors, including pharmaceuticals and diagnostics.
Strategic alliances set up by the Eli Lilly Group :
Of course, Eli Lilly also has allies to rely on for its growth and development. We therefore invite you to discover here some of the partnerships recently set up by this company.
- Dicerna Pharmaceuticals: First, Eli Lilly has signed a partnership with Dicerna Pharmaceuticals with a global licensing and research collaboration focused on the discovery, development and sale of potential new drugs for the treatment of cardiometabolic diseases, neurodegeneration or pain. The two companies plan to collaborate on the development of around ten drugs. The agreement provides for an upfront payment to Dicerna of $100 million and an equity investment of $100 million at a premium. Dicerna could also receive up to $350 million per target in development and commercialization stages.
- AC Immune: Recently, Eli Lilly also signed a collaboration agreement with the Swiss company AC Immune to research and develop small molecule inhibitors of tau protein aggregation for the treatment of Alzheimer's disease and other such neurodegenerative disorders. This partnership will notably draw on AC Immune's technology platform, Morphomer, and Eli Lilly's expertise in clinical development and commercial capabilities. Initially, it will involve the molecule ACI-3024 with an initial payment of 80 million Swiss francs to AC Immune and $50 million in exchange for an option for an equity stake.